-
Become a Global Leader in Paediatric and Women’s Health
We are patient-centered, addressing the unmet medical needs in six therapeutic fields...
RESEARCH AND DEVELOPMENT
Sustaining Innovation...
-
70+
Marketed Products(*pharmaceuticals, diagnostic devices, and medical nutrition products, etc. )
-
26+
Clinical Pipeline
-
16.5%
R&D investment as a percentage of sales revenue in 2023
To challenge, to create, to push the boundaries of what is possible...
Latest News
-
2024-11-20
Chinese Monoclonal Anti-IL-1β Breakthrough: Acute Gout Arthritis Treatment Impresses at ACR 2024Learn More
-
2024-11-11
World ADC San Diego 2024: GenSci showcases two innovative pipeline programsLearn More
-
2024-11-07
Welcome to Visit Us at MEDICA 2024Learn More
-
2024-10-25
GenSci' s Inaugural R&D Day 2024: Innovation in Gene, Science in Actionsuccessfully concluded on October 17, 2024
Learn More
-
2024-07-26
Zhejiang University – GenSci Joint Research Center of Children’s Health establishedLearn More
-
2024-07-09
R&D Innovation Accelerator: Shanghai Children's Hospital and GenSci Ink Strategic Cooperation AgreementTwo Sides will Collaboratively Set Up a R&D Center
Learn More
-
2024-07-03
GenSci Invites you to join us in CPHI South East Asia 2024Join us at Booth H23 from July 10 to 12, 2024 to explore GenSci's flagship products.
Learn More
-
2024-06-28
China's First Aqueous Solution Progesterone Injection, Jin Sai Xin? ApprovedA further step towards GenSci's vision of becoming a global leader in Pediatric and Women's Health
Learn More
-
2024-06-19
GenSci and TWi Reach Exclusive Import and Distribution Agreement for Megaxia?Under this agreement, TWi authorizes GenSci Singapore as the sole distributor of Megaxia? in mainland China, Hong Kong, Macau, and Singapore, responsible for the marketing and promotion of this product.
Learn More
-
2024-06-05
Visit GenSci at CPhI China 2024At Booth W4E59, See you there!
Learn More
-
2024-05-26
NMPA Approves Genakumab Injection for Clinical Trial Commencementwhich marks the initiation of bioequivalence studies for the new formulation of Genakumab Injection
Learn More
-
2024-05-17
Jintrolong? PEG-SOMATROPIN from GenSci highlighted at ECE 2024Jintrolong? PEG-SOMATROPIN was highlighted during the Growth Hormone Research Society (GRS) symposium at the largest endocrine event in Europe
Learn More
-
2024-04-11
R&D Progress: NMPA Approves Genakumab to the MarketMajor R&D Progress
Learn More
-
2023-12-22
GenSci Launches Global Innovation Hub in ShanghaiThe Establishment of the Facility Demonstrates the Company's Commitment to Delivering Differentiated Solutions to Gynecology and Pediatrics Challenges
Learn More